|
Match
|
Document |
Document Title |
|
|
US20120034305 |
SOLID DISPERSING VACCINE COMPOSITION FOR ORAL DELIVERY
The invention disclosed herein relate to an oral vaccine in which the vaccine composition and adjuvant(s) are carried on a solid fast-dispersing dosage form. The vaccines are targeted toward... |
|
|
US20110151005 |
METHODS AND MEANS FOR SOFT TISSUE ENGINEERING
Cellfree adipose tissue extracts, implants including the same and methods for the preparation thereof. The extracts and implants are capable of inducing adipogenesis and angiogenesis and are,... |
|
|
US20110196502 |
Methods of Using Water-Soluble Inorganic Compounds for Implants
A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic... |
|
|
US20120148671 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20140242170 |
Corticosteroids for the Treatment of Joint Pain
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing,... |
|
|
US20110293721 |
PIROXICAM-CONTAINING MATRIX PATCHES AND METHODS FOR THE TOPICAL TREATMENT OF ACUTE AND CHRONIC PAIN AND INFLAMMATION THEREWITH
This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly... |
|
|
US20120207837 |
BIOERODIBLE MATRIX FOR TISSUE INVOLVEMENT
Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting... |
|
|
US20110064810 |
TISSUE ENGINEERING METHOD FOR ORGAN RECONSTRUCTION USING INJECTABLE MATRIX
The various embodiments herein relate to an injectable matrix used for regeneration, reconstruction, repair or replacement of organ or tissue. The injectable matrix consists of a synthetic and... |
|
|
US20100316720 |
Use of an extract from snow algae in cosmetic or dermatological formulations
The present invention relates to the use of an extract from snow algae, especially an extract from Chlamydocapsa sp (snow algae) in cosmetic and/or pharmaceutical products. More particularly, the... |
|
|
US20120114754 |
RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient,... |
|
|
US20120107394 |
IMMUNO-COMPATIBLE HYDROGEL SYSTEM
An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel,... |
|
|
US20110097406 |
METHODS AND COMPOSITIONS FOR RETAINING ECM MATERIALS IN HYDROGELS
The present invention provides cell-laden and/or extracellular matrix material laden hydrogels for use in tissue engineering and methods for producing such hydrogels. In some particular... |
|
|
US20110066182 |
Tissue Sealant for Use in Non Compressible Hemorrhage
ClotFoam is a surgical sealant and hemostatic agent designed to be used in cases of non-compressible hemorrhage. It can be applied in the operating room through laparoscopic ports, or directly... |
|
|
US20120034306 |
POLYMERIC DRUG DELIVERY SYSTEMS AND PROCESSES FOR PRODUCING SUCH SYSTEMS
The subject invention relates to implants for delivery of therapeutic agents such as opioids, and the manufacture and uses of such implants. |
|
|
US20150182456 |
HYDROGEL VACCINE FORMULATIONS
This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material... |
|
|
US20120294938 |
PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION
Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active... |
|
|
US20110052505 |
Post-biopsy cavity treatment implants and methods
A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix... |
|
|
US20110104282 |
New Therapy of Treatment of the Irritable Bowel Syndrome
The invention provides for new methods for treatment and diagnosis of irritable bowel syndrome (IBS). In particular, there is disclosed the use of a Chlamydia activating agent and one or several... |
|
|
US20150118309 |
PREPARATION FOR PERCUTANEOUS ABSORPTION CONTAINING ROTIGOTINE
Exemplary embodiments of the present invention relate to a method for preparing a preparation for percutaneous absorption, which includes rotigotine as an active ingredient, and more specifically,... |
|
|
US20150098997 |
Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of... |
|
|
US20120282340 |
DRUG DELIVERY SYSTEM
The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-β) selective agonist. The wafers of the present... |
|
|
US20100330141 |
PRODUCT FOR ABSORPTION PURPOSES
A product for absorption purposes comprises a water insoluble support matrix substituted with a hydrophobic entity and a positively charged entity. The hydrophobic entity comprises di-alkyl... |
|
|
US20110236454 |
INJECTABLE DRUG DELIVERY FORMULATION
The invention provides an injectable formulation that includes an active agent; a biocompatible solvent system, crosslinkable polymers such as polysaccharides; and crosslinking agents; wherein the... |
|
|
US20100316719 |
B-1,3-GLUCAN-DERIVED POLYALDEHYDE/POLYAMINE HYDROGEL
The present invention provides a combination product which comprises: (1) a polyaldehyde obtained by introducing an aldehyde group into a branched glucose in a β-1,3-glucan, and(2) a polyamine... |
|
|
US20110020451 |
TAMPER-RESISTANT DOSAGE FORM FOR OXIDATION-SENSITIVE OPIOIDS
Thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, comprising an opioid (A),a free physiologically acceptable acid (B) in an amount of from 0.001 to 5.0 wt.-%,... |
|
|
US20120183606 |
DRUG DELIVERY SYSTEM COMPRISING POLYOXAZOLINE AND A BIOACTIVE AGENT
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of... |
|
|
US20110052685 |
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN
Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon... |
|
|
US20110293720 |
PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM
The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one... |
|
|
US20150050341 |
METHODS AND COMPOSITIONS FOR RNAI-BASED CANCER TREATMENT
The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers. |
|
|
US20130280329 |
METHODS AND COMPOSITIONS FOR RNAI-BASED CANCER TREATMENT
The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers. |
|
|
US20110104281 |
METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND
A method for treating pain, particularly non-inflammatory musculoskeletal pain such as myofascial pain or back pain, in a subject comprises administering to the subject a substituted... |
|
|
US20110151003 |
TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY
A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the... |
|
|
US20120107383 |
OSTEOCONDUCTIVE MATRICES COMPRISING CALCIUM PHOSPHATE PARTICLES AND STATINS AND METHODS OF USING THE SAME
Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive... |
|
|
US20110097405 |
ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM
The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present... |
|
|
US20140141079 |
PRAMIPEXOLE ONCE-DAILY DOSAGE FORM
An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically... |
|
|
US20100316718 |
ACTIVATED FOAM
The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium... |
|
|
US20130039981 |
Quick Dissolving, Long Acting Zinc Therapeutic Formulations
The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive... |
|
|
US20130171256 |
ALCOHOL-RESISTANT EXTENDED RELEASE DOSAGE FORMS COMPRISING VENLAFAXINE
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically... |
|
|
US20090142400 |
ANALGESIC COATED MEDICAL PRODUCT
Described are medical products including an analgesic such as lidocaine, bupivicaine, or a mixture thereof. Such medical products can find use in pain relief, particularly after surgery, and can... |
|
|
US20110104273 |
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE
Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and... |
|
|
US20110256201 |
HYDROLYZED HYDROGELS
The invention provides methods of making hydrolyzed cross-linked polyvinyl alcohol (PVA) hydrogels by polymerizing vinyl acetate (VAc) monomers to polyvinyl acetate (PVAc) polymer network by... |
|
|
US20120141583 |
ALCOHOL RESISTANT DOSAGE FORMS
Opioid controlled release formulation resistant to alcohol extraction of the opioid. |
|
|
US20110165248 |
PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(E-CAPROLACTONE)
The present invention relates to pharmaceutical dosage forms, for example to pharmaceutical dosage forms comprising poly(ε-caprolactone), and processes of manufacture, uses, and methods of... |
|
|
US20110217371 |
CONTROLLED-RELEASE MICROPARTICLES AND METHOD OF PREPARING SAME
Disclosed is a controlled-release microparticle: including a matrix comprising a pharmacologically active component; and a controlled-release layer comprising a substance which forms a... |
|
|
US20130171257 |
EXTENDED RELEASE OPIOID ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME
This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix. |
|
|
US20120087982 |
EXTENDED RELEASE OPIOID ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME
This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix. |
|
|
US20100303911 |
Hydrogel systems
A method of in situ hydrogel polymerization is provided. The method comprises combining a backbone polymer with an in situ polymerizable group to form a prepolymer solution which is administered... |
|
|
US20110111033 |
HYDROGEL WITH COVALENTLY CROSSLINKED CORE
A novel hydrogel system is provided. The hydrogel system comprises a biocompatible hydrogel core having dispersed therein a covalently crosslinked polymer matrix. The hydrogel system is useful per... |
|
|
US20130115282 |
POLYVALENT POLYMERIC MATRIX FOR MODIFIED RELEASE SOLID ORAL PREPARATIONS AND METHOD OF PREPARATION THEREOF
A polymeric matrix for oral administration with modified release and taste masking properties is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of... |
|
|
US20120269893 |
Compositions Comprising Solid Particles Encapsulated In A Cross-Linked Silicone Matrix, And Methods Of Making The Same
The present invention relates to topical compositions containing solid particles that are stabilized via encapsulation into a cross-linked silicone matrix. The solid particles are preferably... |